Immuron Limited - ADR

Immuron Limited - ADR

IMRN - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$7.21M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Immuron Limited - ADRImmuron Limited - ADR-3.1--60%0.9-
$-1.34

Current Fair Value

251% downside

Overvalued by 251% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$7.21 Million
Enterprise Value$-1,807,534.00
Earnings per Share$-0.5
Beta0.51
Outstanding Shares8,134,000

Return

Return on Equity-60.24%ROE
Return on Assets-51.03%
Return on Invested Capital-68.03%

Valuation & Multiples

P/E Ratio-3.1P/E Ratio
PEG-7.59PEG
Price to Sales0.89Price to Sales
Price to Book Ratio0.89Price to Book Ratio
Enterprise Value to Revenue0.12
Enterprise Value to EBIT-0.17
Enterprise Value to Net Income0
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 28, 2026
EPS Estimate
$-0.00
Consensus analyst estimate
Revenue Estimate
$2.75 M
Consensus analyst estimate

Next Earnings Call

Expected Date
February 19, 2027
EPS Estimate
$-0.01
Consensus analyst estimate
Revenue Estimate
$3.36 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.00%▼ 1.05%
Total Invested$32▼ 99.96%
Investors Holding1▼ 5.00%

About Immuron Limited

7 employees
CEO: Steven George Lydeamore

Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Re...

Immuron Limited Insider Information FAQ

Stockcircle tracks 2 top investors with a current 13F position in Immuron Limited. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.